Lead Product(s) : Sunvozertinib
Therapeutic Area : Oncology
Study Phase : Phase I/ Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
U.S. FDA Granted Priority Review to Dizal's Sunvozertinib New Drug Application
Details : DZD9008 (sunvozertinib) is an oral, potent, irreversible, & selective EGFR tyrosine kinase inhibitor. It is being evaluated for the treatment of Exon20ins-mutated locally advanced or metastatic NSCLC.
Product Name : DZD9008
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
January 07, 2025
Lead Product(s) : Sunvozertinib
Therapeutic Area : Oncology
Highest Development Status : Phase I/ Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Sunvozertinib
Therapeutic Area : Oncology
Study Phase : Approved FDF
Sponsor : Burning Rock Dx
Deal Size : Inapplicable
Deal Type : Inapplicable
NMPA Grants Approval For NGS-Based Companion Diagnostic For Lung Cancer
Details : DZD9008 (sunvozertinib) is an oral, potent, irreversible, & selective EGFR tyrosine kinase inhibitor. It is indicated for the treatment of Exon20ins-mutated locally advanced or metastatic NSCLC.
Product Name : DZD9008
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
October 10, 2024
Lead Product(s) : Sunvozertinib
Therapeutic Area : Oncology
Highest Development Status : Approved FDF
Sponsor : Burning Rock Dx
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Sunvozertinib
Therapeutic Area : Oncology
Study Phase : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
WU-KONG1B Study Shows Sunvozertinib Efficacy in EGFR Exon 20 NSCLC
Details : DZD9008 (sunvozertinib) is an oral, potent, irreversible, & selective EGFR tyrosine kinase inhibitor. It is being evaluated for the treatment of Exon20ins-mutated locally advanced or metastatic NSCLC.
Product Name : DZD9008
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
September 16, 2024
Lead Product(s) : Sunvozertinib
Therapeutic Area : Oncology
Highest Development Status : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Sunvozertinib
Therapeutic Area : Oncology
Study Phase : Phase I/ Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Dizal Submits NDA to FDA for Sunvozertinib in Treating NSCLC with EGFR
Details : DZD9008 (sunvozertinib) is an oral, potent, irreversible, & selective EGFR tyrosine kinase inhibitor. It is being evaluated for the treatment of Exon20ins-mutated locally advanced or metastatic NSCLC.
Product Name : DZD9008
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
August 11, 2024
Lead Product(s) : Sunvozertinib
Therapeutic Area : Oncology
Highest Development Status : Phase I/ Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Sunvozertinib
Therapeutic Area : Oncology
Study Phase : Phase I/ Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
FDA Grants Breakthrough Designation to Sunvozertinib for NSCLC Treatment
Details : DZD9008 (sunvozertinib), an EGFR tyrosine kinase inhibitor, is being studied for Exon20ins-mutated advanced non-small cell lung cancer.
Product Name : DZD9008
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
July 04, 2024
Lead Product(s) : Sunvozertinib
Therapeutic Area : Oncology
Highest Development Status : Phase I/ Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Sunvozertinib
Therapeutic Area : Oncology
Study Phase : Phase I/ Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Dizal Highlights Sunvozertinib's Efficacy for Lung Cancer with EGFR Exon 20 Mutations
Details : DZD9008 (sunvozertinib) is an oral, potent, irreversible, & selective EGFR tyrosine kinase inhibitor. It is being evaluated for the treatment of Exon20ins-mutated locally advanced or metastatic NSCLC.
Product Name : DZD9008
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
May 24, 2024
Lead Product(s) : Sunvozertinib
Therapeutic Area : Oncology
Highest Development Status : Phase I/ Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Sunvozertinib
Therapeutic Area : Oncology
Study Phase : Phase I/ Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Sunvozertinib Meets Primary Endpoint in NSCLC with EGFR Exon 20 Insertions
Details : DZD9008 (sunvozertinib) is an oral, potent, irreversible, & selective EGFR tyrosine kinase inhibitor. It is being evaluated for the treatment of Exon20ins-mutated locally advanced or metastatic NSCLC.
Product Name : DZD9008
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
February 06, 2024
Lead Product(s) : Sunvozertinib
Therapeutic Area : Oncology
Highest Development Status : Phase I/ Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Sunvozertinib
Therapeutic Area : Oncology
Study Phase : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : DZD9008 (sunvozertinib) is an investigational, oral tyrosine kinase inhibitor (TKI) specifically designed to selectively target epidermal growth factor receptor (EGFR) exon20 insertion (exon20ins) mutations for the treatment of advanced NSCLC.
Product Name : DZD9008
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
October 01, 2023
Lead Product(s) : Sunvozertinib
Therapeutic Area : Oncology
Highest Development Status : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Sunvozertinib
Therapeutic Area : Oncology
Study Phase : Phase III
Sponsor : Dizal Pharmaceutical
Deal Size : Undisclosed
Deal Type : Partnership
Details : The partnership aims to accelerate the development of DZD9008 (sunvozertinib), an irreversible EGFR inhibitor discovered by Dizal scientists targeting a wide spectrum of EGFR mutations with wild-type EGFR selectivity, for patients with EGFR Exon20ins mut...
Product Name : DZD9008
Product Type : Other Small Molecule
Upfront Cash : Undisclosed
June 09, 2023
Lead Product(s) : Sunvozertinib
Therapeutic Area : Oncology
Highest Development Status : Phase III
Sponsor : Dizal Pharmaceutical
Deal Size : Undisclosed
Deal Type : Partnership
Lead Product(s) : Sunvozertinib
Therapeutic Area : Oncology
Study Phase : Phase I/ Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Dizal to Demonstrate the Strength and Rapid Acceleration of its Clinical Portfolio at ASCO 2022
Details : Sunvozertinib (DZD9008) shows superior efficacy in NSCLC patients harboring EGFR exon 20 insertion mutations after platinum and anti-PD(L)1 treatment failures. It also demonstrates superior efficacy in patients after platinum and anti-PD(L)1 treatment fa...
Product Name : DZD9008
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
May 27, 2022
Lead Product(s) : Sunvozertinib
Therapeutic Area : Oncology
Highest Development Status : Phase I/ Phase II
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable